Analyst Price Target Update on Geron Corporation (NASDAQ:GERN)

Geron Corporation (NASDAQ:GERN) stock has received a short term price target of $ 7.5 from 3 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $2.18. The higher estimate of target price is $10 , while the lower price target estimate is $6

For the current week, the company shares have a recommendation consensus of Buy.

On the companys insider trading activities, The Securities and Exchange Commission has divulged that Bloom Olivia Kyusuk, officer (EVP, Chief Financial Officer) of Geron Corp, had unloaded 2,380 shares at an average price of $3.84 in a transaction dated on May 29, 2015. The total value of the transaction was worth $9,139.

Geron Corporation (NASDAQ:GERN) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.06 points or 2.17% at $2.71 with 1,894,299 shares getting traded. Post opening the session at $2.75, the shares hit an intraday low of $2.69 and an intraday high of $2.78 and the price was in this range throughout the day. The company has a market cap of $431 million and the number of outstanding shares have been calculated to be 158,960,260 shares. The 52-week high of Geron Corporation (NASDAQ:GERN) is $5.3 and the 52-week low is $2.3.

Geron Corporation (Geron) is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in one segment, the discovery and development of therapeutic products for oncology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides a capacity for limitless, uncontrolled proliferation. Telomerase consists of two essential components: a ribonucleic acid (RNA) template (hTR), which binds to the telomere, and a catalytic subunit (hTERT) with reverse transcriptase activity, which adds a specific DNA (deoxyribonucleic acid) sequence to the chromosome ends. Using its nucleic acid chemistry, the Company designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.